Phase 4 N=71 Adding Liraglutide to High Dose Insulin: Breaking the Cycle
Type 2 Diabetes Mellitus · Obesity
Primary: Glycemic Control Measured by HbA1c — 7.9; 8.9 Percent HbA1c
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Incidence of Sleep-disordered Breathing and Upper Airway Collapsibility in Postpartum Patients and Its Intervention
Sleep Disordered Breathing · Upper Airway Collapsibility · Upper Airway Obstruction
Primary: Apnea-hypopnea Index (AHI), Defined as the Number of Apneas and Hypopneas Per Hour of Sleep — 4.5; 7.7 Apneas and hypopneas per hour of sleep
Phase 3 N=183 Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye
Dry Eye
Primary: Ocular Surface Disease Index (OSDI©) Questionnaire — 19.3; 19.3; 7.3; 7.9 points
N/A N=49 Understanding Disparities in Healthcare and Primary Care Provider Quality
Physical Disability
Primary: Satisfaction With Medical Care Survey — 3.4; 3.8; 3.6; 3.0 units on a scale
Phase 3 N=27 Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Clostridium Enterocolitis · Pseudomembranous Colitis
Primary: Nitazoxanide — 27 participants
N/A N=88 Cognitive-Behavioral Therapy in Veterans With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30
Phase 3 N=144 Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee
Articular Cartilage Defect
Primary: Change From Baseline to Week 104 for the Participant's Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain and Function (Sports and Recreational Activities) Scores…
Phase 3 N=255 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 95.3; 90.5; 97.7; 97.6 percentage of participants
Phase 2 N=215 A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis
Bacterial Vaginosis
Primary: Cure of Bacterial Vaginosis — 33; 42; 11; 31 Participants
Phase 2 N=87 A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease
Sickle Cell Disease
Primary: Change in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiary — -0.1802; -0.1352; -0.1001 Proportion of days with pain
Phase 2 N=129 A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
Multiple Sclerosis
Primary: Annualized Relapse Rate — 0.45; 0.34 Relapse per year — p=0.3797
Phase 4 N=50 Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older
Influenza
Primary: Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies — 30 Participants
Phase 2 N=6 BGS649 Monotherapy in Moderate to Severe Endometriosis Patients
Endometriosis
Primary: Proportion of Patients Who Develop 2 or More Follicles With Diameter 16 mm or Larger — 2; 2; 0 Participants
N/A N=450 Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Primary: Absolute Change in % Hemoglobin A1c From Baseline at 52 Weeks — 0.04; -0.05; -0.10 Percent Hemoglobin A1c
Phase 3 N=172 Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A
Infections, Streptococcal
Primary: Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Unprimed Group — 0.06; 0.04…